Hirth Jacqueline M, Hatch Sandra S, Lin Yu-Li, Giordano Sharon H, Silva H Colleen, Kuo Yong-Fang
Department of Obstetrics and Gynecology, Center for Interdisciplinary Research in Women's Health, The University of Texas Medical Branch, Galveston, Texas.
Department of Radiation Oncology, The University of Texas Medical Branch, Galveston, Texas.
Cancer. 2018 Jul 1;124(13):2815-2823. doi: 10.1002/cncr.31393. Epub 2018 Apr 18.
Overtreatment is a common concern for patients with ductal carcinoma in situ (DCIS), but this entity is difficult to distinguish from invasive breast cancers in administrative claims data sets because DCIS often is coded as invasive breast cancer. Therefore, the authors developed and validated algorithms to select DCIS cases from administrative claims data to enable outcomes research in this type of data.
This retrospective cohort using invasive breast cancer and DCIS cases included women aged 66 to 70 years in the 2004 through 2011 Texas Cancer Registry (TCR) data linked to Medicare administrative claims data. TCR records were used as "gold" standards to evaluate the sensitivity, specificity, and positive predictive value (PPV) of 2 algorithms. Women with a biopsy enrolled in Medicare parts A and B at 12 months before and 6 months after their first biopsy without a second incident diagnosis of DCIS or invasive breast cancer within 12 months in the TCR were included. Women in 2010 Medicare data were selected to test the algorithms in a general sample.
In the TCR data set, a total of 6907 cases met inclusion criteria, with 1244 DCIS cases. The first algorithm had a sensitivity of 79%, a specificity of 89%, and a PPV of 62%. The second algorithm had a sensitivity of 50%, a specificity of 97%. and a PPV of 77%. Among women in the general sample, the specificity was high and the sensitivity was similar for both algorithms. However, the PPV was approximately 6% to 7% lower.
DCIS frequently is miscoded as invasive breast cancer, and thus the proposed algorithms are useful to examine DCIS outcomes using data sets not linked to cancer registries. Cancer 2018;124:2815-2823. © 2018 American Cancer Society.
过度治疗是导管原位癌(DCIS)患者普遍关注的问题,但在行政索赔数据集中,该实体难以与浸润性乳腺癌区分开来,因为DCIS常被编码为浸润性乳腺癌。因此,作者开发并验证了从行政索赔数据中筛选DCIS病例的算法,以便在此类数据中进行结局研究。
这项回顾性队列研究纳入了2004年至2011年德克萨斯州癌症登记处(TCR)数据中年龄在66至70岁之间且与医疗保险行政索赔数据相关联的浸润性乳腺癌和DCIS病例。TCR记录用作“金”标准,以评估两种算法的敏感性、特异性和阳性预测值(PPV)。纳入在首次活检前12个月和活检后6个月参加医疗保险A部分和B部分且在TCR中12个月内未发生第二次DCIS或浸润性乳腺癌确诊事件的活检女性。选取2010年医疗保险数据中的女性在一般样本中测试算法。
在TCR数据集中,共有6907例病例符合纳入标准,其中1244例为DCIS病例。第一种算法的敏感性为79%,特异性为89%,PPV为62%。第二种算法的敏感性为50%,特异性为97%,PPV为77%。在一般样本中的女性中,两种算法的特异性都很高且敏感性相似。然而,PPV约低6%至7%。
DCIS经常被错误编码为浸润性乳腺癌,因此所提出的算法对于使用与癌症登记处无关的数据集来研究DCIS结局很有用。《癌症》2018年;124:2815 - 2823。©2018美国癌症协会。